Literature DB >> 2987424

Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.

D A Decker, M Al Sarraf, C Kresge, D Austin, H I Wilner.   

Abstract

Seventeen patients with malignant gliomas recurrent after chemotherapy and/or radiation failure were treated with aziridinylbenzoquinone (AZQ) at a dose of 20-15 mg/M2 weekly for four weeks followed by a two week rest. Regression of disease was observed in four patients, 4/17 (24%) for 35, 15+, 40+, and 10 weeks. Toxicity was limited to moderate reversible myelosuppression. AZQ in this dose and schedule has limited but definite activity in patients with malignant gliomas progressive after primary radiation therapy failure.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2987424     DOI： 10.1007/bf00165167

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  4 in total

1.  Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors.

Authors:  V A Levin; D C Crafts; D M Norman; P B Hoffer; J P Spire; C B Wilson
Journal:  J Neurosurg       Date:  1977-09       Impact factor: 5.115

2.  A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.

Authors:  L G Feun; W K Yung; M E Leavens; M A Burgess; E A Obbens; A Y Bedikian; N Savaraj; D J Stewart; R S Benjamin; W S Fields
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

3.  Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).

Authors:  R T Eagan; R P Dinapoli; R C Hermann; R V Groover; D D Layton
Journal:  Am J Clin Oncol       Date:  1983-10       Impact factor: 2.339

4.  Potential CNS antitumor agents VI: aziridinylbenzoquinones III.

Authors:  J S Driscoll; L Dudeck; G Congleton; R I Geran
Journal:  J Pharm Sci       Date:  1979-02       Impact factor: 3.534
  4 in total
  6 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

2.  A phase II study of diaziquone in children with recurrent or progressive primary brain tumors: a report from the Childrens Cancer Study Group.

Authors:  L J Ettinger; N Ru; M Krailo; K S Ruccione; W Krivit; G D Hammond
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

3.  Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.

Authors:  P Paoletti; G Butti; R Knerich; P Gaetani; R Assietti
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

4.  Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the Brain Tumor Study Group.

Authors:  M G Malkin; S B Green; D P Byar; T A Strike; P C Burger; F S Vogel; D A Pistenmaa; M S Mahaley; J Ransohoff; W R Shapiro
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.

Authors:  R T Eagan; R P Dinapoli; T L Cascino; B Scheithauer; B P O'Neill; J R O'Fallon
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

6.  Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.

Authors:  Victor A Levin; Sandra Ictech; Kenneth R Hess
Journal:  BMC Cancer       Date:  2007-06-22       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.